Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $70 on Varian Medical Systems Following Meeting with Management

Related VAR
Benzinga's M&A Chatter for Wednesday December 17, 2014
Doctors at Innovative Cancer Institute In Miami Use New Radiosurgery System To Treat Tumor Encroaching On Patient's Spinal Cord

Cantor Fitzgerald reiterated its Hold rating on Varian Medical Systems (NYSE: VAR) but raised its price target from $63 to $70.

Cantor Fitzgerald said, "We hosted an investor meeting with Varian management at company headquarters as part of our Bay Area bus tour, and we note the following takeaways: 1) reimbursement is less of an overhang, but freestanding has not yet turned a corner; 2) EDGE represents a dedicated radiosurgery solution, but the early ramp should be gradual until the lung opportunity develops; and 3) margins are stable and improving. While macro concerns keep us on the sidelines (U.S. hospital capex, FX headwinds), we are raising our price target from $63 to $70 to give the company credit for its solid market leadership position."

Varian Medical Systems closed at $69.38 on Monday.

Latest Ratings for VAR

DateFirmActionFromTo
Oct 2014JP MorganMaintainsOverweight
Oct 2014JefferiesMaintainsBuy
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for VAR
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (VAR)

Around the Web, We're Loving...

Get Benzinga's Newsletters